



We claim:

1. A method of treating or preventing Alzheimer's disease in a subject in need of such treatment comprising administering a therapeutically effective amount of a compound of formula I or  
5 a pharmaceutically acceptable salt thereof:




wherein  $\text{Ar}$  is



\* indicates a mixture of isomers at this carbon


10









$\text{R}_{10}$  is H or OH;


X is O or an electron pair;

W is




*Q* is







Z is H or Z and Q taken together are  $-(CH_2)_3-$  or  $-(CH_2)_4-$   
U is



$R_3$  is  $C_{1-11}$ -alkyl or




wherein  $R_{20}$  is H or  $C_{1-10}$ -alkyl; and Ac is formyl or






10

wherein  $R_{21}$  is  $C_{1-10}$ -alkyl;

L is



R<sub>2</sub> is



5

m is 0, 1 or 2;

p is 0, 1 or 2; and

q is 0, 1, or 2;

an epimer or racemate thereof.

2. A method of treating Alzheimer's disease in a subject in need of such treatment comprising administering to the subject a compound disclosed in claim 1, or a pharmaceutically acceptable salt thereof.

5


3. A method of treating Alzheimer's disease by modulating the activity of beta amyloid converting enzyme, comprising administering to a subject in need of such treatment a compound disclosed in claim 1, or a pharmaceutically acceptable salt thereof.

10

4. The method according to claim 1, further comprising the administration of a P-gp inhibitor, or a pharmaceutically acceptable salt thereof.



15

5. A method of treating a subject who has, or in preventing a subject from getting, a disease or condition selected from the group consisting of Alzheimer's disease, for helping prevent or delay the onset of Alzheimer's disease, for treating subjects with mild cognitive impairment (MCI) and preventing or delaying the onset of Alzheimer's disease in those who would progress from MCI to AD, for treating Down's syndrome, for treating humans who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, for treating cerebral amyloid angiopathy and preventing its potential consequences, i.e. single and recurrent lobar hemorrhages, for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, frontotemporal dementias with parkinsonism (FTDP), dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, or diffuse Lewy body type of Alzheimer's disease and who is in need of such treatment which includes administration of a therapeutically effective amount of a compound of formula (I)




wherein Ar is

5




\* indicates a mixture of isomers at this carbon










R<sub>10</sub> is H or OH;

X is O or an electron pair;

10 W is





Q is




5

Z is H or Z and Q taken together are -(CH<sub>2</sub>)<sub>3</sub>- or -(CH<sub>2</sub>)<sub>4</sub>-


U is

 $R_3$  is  $C_{1-11}$ -alkyl or

5




wherein  $R_{20}$  is H or  $C_{1-10}$ -alkyl; and Ac is formyl orwherein  $R_{21}$  is  $C_{1-10}$ -alkyl;

L is



10

 $\text{---} (CH_2)_q \text{-COR}_2$  : $R_2$  is




m is 0, 1 or 2;

p is 0, 1 or 2; and

5       q is 0, 1, or 2;

an epimer or racemate thereof.

6.      The method according to any of claims 1-5 wherein Ar  
10     is




7.      The method according to any of claims 1-5 wherein W  
is selected from the group consisting of  $\text{-SO}_2\text{-}$  and  $\text{-CO-}$ .

15

8.      The method according to any of claims 1-5 wherein W is  
 $\text{-CO-}$ .

9. The method according to any of claims 1-5 wherein Q is selected from the group consisting of



5 10. The method according to any of claims 1-5 wherein Q is




11. The method according to any of claims 1-5 wherein Q is



10

12. The method according to any of claims 1-5 wherein U is selected from the group consisting of




15


13. The method according to any of claims 1-5 wherein U is



20 14. The method according to any of claims 1-5 wherein  $-\text{O-L}$   
is




15. The method according to any of claims 1-5 wherein  $-\text{O-L}$   
is



16. The method according to any of claims 1-5 wherein R<sub>2</sub> is selected from the group consisting of NH-tBu or NH-Ph.

5

17. A method of treating or preventing Alzheimer's disease in a subject in need of such treatment comprising administering a therapeutically effective amount of a compound selected from the group consisting of:




Compound	Ar-W-	Q	U	L
A				

10


B				
C				
D				
E				
F				
G				
H				
I				

J				
K				
L				
M				
N				
O				
P				
Q				

R				
S				
T				






wherein \* denotes all the possible stereoisomers at the particular carbon, and mixtures thereof;





5


or a mixture thereof;



10




5




or pharmaceutically acceptable salts thereof.


10           18. Use of a compound of Formula (I) or a pharmaceutical salt thereof, in the manufacture of a medicament for the treatment or prevention of conditions selected from the group consisting of Alzheimer's disease, mild cognitive impairment (MCI) Down's syndrome, Hereditary Cerebral Hemorrhage with  
15           Amyloidosis of the Dutch-Type, cerebral amyloid angiopathy, degenerative dementias, including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, frontotemporal dementias with parkinsonism (FTDP), dementia associated with progressive supranuclear palsy, dementia  
20           associated with cortical basal degeneration, or diffuse Lewy body type of Alzheimer's disease:



5 wherein Ar is




\* indicates a mixture of isomers at this carbon




R<sub>10</sub> is H or OH;

10 X is O or an electron pair;


W is



Q is




5




Z is H or Z and Q taken together are  $-(\text{CH}_2)_3-$  or  $-(\text{CH}_2)_4-$


U is



5 R<sub>3</sub> is C<sub>1-11</sub>-alkyl or




wherein R<sub>20</sub> is H or C<sub>1-10</sub>-alkyl; and Ac is formyl or







wherein R<sub>21</sub> is C<sub>1-10</sub>-alkyl;

10 L is



$-(\text{CH}_2)_q-\text{COR}_2$  :

R<sub>2</sub> is




m is 0, 1 or 2;

p is 0, 1 or 2; and




5 q is 0, 1, or 2;

an epimer or racemate thereof.


19. A method for inhibiting beta-secretase activity,  
 comprising contacting an effective amount for inhibition of a  
 10 compound of formula (I)



15 wherein Ar is




\* indicates a mixture of isomers at this carbon




R<sub>10</sub> is H or OH;

X is O or an electron pair;

5 W is




Q is




5


Z is H or Z and Q taken together are  $-(CH_2)_3-$  or  $-(CH_2)_4-$   
U is



R<sub>3</sub> is C<sub>1-11</sub>-alkyl or










5 wherein R<sub>20</sub> is H or C<sub>1-10</sub>-alkyl; and Ac is formyl or



wherein R<sub>21</sub> is C<sub>1-10</sub>-alkyl;




L is



or

—(CH<sub>2</sub>)<sub>q</sub>-COR<sub>2</sub> :

10 R<sub>2</sub> is



m is 0, 1 or 2;


p is 0, 1 or 2; and

5 q is 0, 1, or 2;


an epimer or racemate thereof.

20. A method for inhibiting cleavage of an amyloid precursor protein (APP) isotype at a site in the APP isotype that  
10 is susceptible to cleavage, comprising contacting said APP isotype with an effective cleavage inhibitory amount of a compound of formula (I) or pharmaceutically acceptable salt thereof:


15



wherein Ar is




\* indicates a mixture of isomers at this carbon





R<sub>10</sub> is H or OH;


5 X is O or an electron pair;

W is




Q is






R<sub>3</sub> is C<sub>1-11</sub>-alkyl or









5        wherein R<sub>20</sub> is H or C<sub>1-10</sub>-alkyl; and Ac is formyl or



wherein R<sub>21</sub> is C<sub>1-10</sub>-alkyl;



L is



or

—(CH<sub>2</sub>)<sub>q</sub>—COR<sub>2</sub> :

10    R<sub>2</sub> is




m is 0, 1 or 2;

p is 0, 1 or 2; and


5 q is 0, 1, or 2;

an epimer or racemate thereof.


21. A method for inhibiting production of amyloid beta peptide (A beta) in a cell, comprising administering to said 10 cell an effective inhibitory amount of a compound of formula (I) or pharmaceutically acceptable salt thereof:



15 wherein Ar is




\* indicates a mixture of isomers at this carbon





R<sub>10</sub> is H or OH;

X is O or an electron pair;

5 W is




Q is




Z is H or Z and Q taken together are  $-(CH_2)_3-$  or  $-(CH_2)_4-$


U is



$R_3$  is  $C_{1-11}$ -alkyl or




5 wherein  $R_{20}$  is H or  $C_{1-10}$ -alkyl; and Ac is formyl or




wherein  $R_{21}$  is  $C_{1-10}$ -alkyl;




L is



or

10  $R_2$  is





m is 0, 1 or 2;

p is 0, 1 or 2; and

5        q is 0, 1, or 2;

an epimer or racemate thereof.


22. The method of claim 21, wherein the cell is an animal cell.

10


23. The method of claim 22, wherein the animal cell is a mammalian cell.

15        24. The method of claim 23, wherein the mammalian cell is human.

25. A composition comprising beta-secretase complexed with a compound of formula (I):




wherein Ar is



\* indicates a mixture of isomers at this carbon


5



R<sub>10</sub> is H or OH;



X is O or an electron pair;

W is





10

Q is




Z is H or Z and Q taken together are -(CH<sub>2</sub>)<sub>3</sub>- or -(CH<sub>2</sub>)<sub>4</sub>-


U is



R<sub>3</sub> is C<sub>1-11</sub>-alkyl or









5 wherein R<sub>20</sub> is H or C<sub>1-10</sub>-alkyl; and Ac is formyl or



wherein R<sub>21</sub> is C<sub>1-10</sub>-alkyl;





L is



or

—(CH<sub>2</sub>)<sub>q</sub>-COR<sub>2</sub> ;

10 R<sub>2</sub> is



$m$  is 0, 1 or 2;

$p$  is 0, 1 or 2; and


5       $q$  is 0, 1, or 2;

an epimer or racemate thereof.

26. A method for producing a beta-secretase complex comprising the composition of claim 25.


10

27. A method for inhibiting the production of beta-amyloid plaque in an animal, comprising administering to said animal an effective inhibiting amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:




15

wherein Ar is




\* indicates a mixture of isomers at this carbon





$R_{10}$  is H or OH;

X is O or an electron pair;

5 W is




Q is




5

Z is H or Z and Q taken together are  $-(\text{CH}_2)_3-$  or  $-(\text{CH}_2)_4-$   
U is










$\text{R}_3$  is  $\text{C}_{1-11}$ -alkyl or



5  $\text{R}_{20}$  is H or  $\text{C}_{1-10}$ -alkyl; and Ac is formyl or

$\text{R}_{21}$  is  $\text{C}_{1-10}$ -alkyl;





L is



or

$-(\text{CH}_2)_q-\text{COR}_2$  ;

10  $\text{R}_2$  is



is 0, 1 or 2;

is 0, 1 or 2; and


5 is 0, 1, or 2;

an epimer or racemate thereof.


28. The method of claim 27, wherein said animal is a human.

10 29. A method for treating or preventing a disease characterized by beta-amyloid deposits on or in the brain, comprising administering to a subject in need of such treatment or prevention an effective therapeutic amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:


15



wherein Ar is




\* indicates a mixture of isomers at this carbon.




R<sub>10</sub> is H or OH;

5      X is O or an electron pair;

W is




Q is




5


Z is H or Z and Q taken together are  $-(CH_2)_3-$  or  $-(CH_2)_4-$   
U is



$R_3$  is  $C_{1-11}$ -alkyl or









5 wherein  $R_{20}$  is H or  $C_{1-10}$ -alkyl; and Ac is formyl or



wherein  $R_{21}$  is  $C_{1-10}$ -alkyl;





L is



or

—  $(CH_2)_4-COR_2$  —

10  $R_2$  is



m is 0, 1 or 2;

p is 0, 1 or 2; and

5 q is 0, 1, or 2;

an epimer or racemate thereof.

30. A method of treatment according to any of claims 1-6, further comprising administration of one or more therapeutic agents selected from the group consisting of an antioxidant, an anti-inflammatory, a gamma secretase inhibitor, a neurotrophic agent, an acetyl cholinesterase inhibitor, a statin, P-gp inhibitors, an A beta peptide, and an anti-A beta peptide.